Fig. 5: LDAH knockdown increases chemoresistance through ATGL upregulation. | Oncogenesis

Fig. 5: LDAH knockdown increases chemoresistance through ATGL upregulation.

From: Lipid droplet-associated hydrolase (LDAH) knockdown enhances TAG hydrolysis and promotes ovarian cancer progression and chemoresistance

Fig. 5

A Western blot of ATGL in scrambled and LDAH knockdown ES2 cancer cells with or without cisplatin treatment. GAPDH, a loading control. B Cells viability of scrambled control (SCR), LDAH knockdown (shLDAH), and ATGL overexpressing (ATGL OE) ES2 cancer cells. Student’s T-test. TAG levels (mg/dl) (C) and Western blot of CPT1A, ATGL, pNF-ĸB, and NF-ĸB (D) in scrambled control and ATGL-overexpressing ES2 cells. Student’s T-test. E Immunofluorescence images of LDAH, ATGL, and cleaved caspase 3 in excised subcutaneous tumors from Fig. 2F. Scale bars, 100 µm (LDAH/ATGL IF), and 50 µm (cleaved caspase 3 IF). Quantification of fluorescence intensity of ATGL and cleaved caspase 3 are shown on the right. One-way ANOVA followed by Tukey’s multiple comparison test. F Cell viability of scrambled, LDAH knockdown (shLDAH), and atglistatin (50 µM)- treated shLDAH ES2 cells after 8 µM cisplatin treatment for 3 days. Student’s T-test. G BODIPY 493/503 staining (green) of lipid droplets in scrambled, LDAH knockdown (shLDAH), and atglistatin (50 µM)-treated shLDAH ES2 cancer cells. Blue, DAPI. Scale bars, 10 µm. H Western blot of CPT1A, pNFĸB, and NFĸB in scrambled, LDAH knockdown (shLDAH), and atglistatin (50 µM)-treated shLDAH ES2 cancer cells. I Kaplan-Meier survival curve of overall survival (OS) in 212 ovarian cancer patients based on ATGL expression. Red indicates high ATGL expression. *, p < 0.05, ***, p < 0.001. ****, p < 0.0001.

Back to article page